Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user shared progress pictures after 11 months on finasteride and minoxidil, with intermittent microneedling. The community responded positively, noting significant hair regrowth and encouraging continued treatment.

The conversation discusses the variability in effectiveness of medications, including finasteride, and questions whether different manufacturers impact results. The user suggests sharing successful brands to help others identify effective options.

A new hair loss lotion by Dr. Brotzu, expected to regrow up to 5 years of lost hair, is set to be released by Fidia Farmaceutici. It claims to work like minoxidil and finasteride without side effects, but skepticism exists due to its classification as a cosmetic product.

The conversation covers aggressive hair regrowth treatments like Dutasteride, Minoxidil (oral and topical), RU58841, microneedling, and ketoconazole shampoo. It also mentions PRP, laser therapy, GHK-Cu injections, and hormone therapy for maximum regrowth.

A 35-year-old man has used finasteride for 12 years and oral minoxidil at 5 mg for 2 years, achieving significant hair regrowth and density without side effects, avoiding a hair transplant. He recommends consistency with medication and highlights the effectiveness and affordability of oral minoxidil.

The user is experiencing significant hair shedding after three months on oral Dutasteride, Minoxidil, and Vitamin D3, but remains hopeful as shedding can indicate treatment effectiveness. They consider adding topical Minoxidil and dermal needling, while others advise patience.

Switching from topical to oral minoxidil caused prolonged hair shedding without regrowth, leading to the use of both topical and oral minoxidil with oral finasteride. Responses to these treatments vary, emphasizing the need for personalized approaches.

Hair loss affects mental health, with negative comments from others being common. Treatments like finasteride and minoxidil are used, and some focus on self-improvement and humor to handle societal judgments.

A user reported significant hair regrowth using only 1mg finasteride daily over 3.5 years, with no side effects. They stressed patience and consistency, seeing noticeable results after two years.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

Creatine does not increase DHT levels or cause hair loss. Personal experiences vary, but scientific evidence shows no link between creatine and hair loss.

Checking vitamin and hormone levels is important for addressing hair loss, as deficiencies in vitamin D, zinc, and iron can affect hair growth. Treatments like finasteride, minoxidil, and vitamin supplements are used, but addressing deficiencies is crucial for effectiveness.

Minoxidil with alcohol and propylene glycol was more effective than non-alcohol versions, and RU58841 worked best in a non-water-based solution. Oral finasteride showed better results than topical, despite side effects; microneedling and tretinoin worsened hair loss, and PRP was only helpful when younger.

A user tried various hair growth treatments, including drinking topical minoxidil, using oral minoxidil and finasteride, and applying GHK-Cu, growth hormone peptides, and liposomal sulforaphane. They experienced thicker hair, while others discussed the risks and benefits of these methods.

A user is starting a microneedling regimen for hair loss, using Derminator 2, ketoconazole shampoo, castor oil, and multivitamins. They plan to provide monthly updates on their progress.

The user stopped using minoxidil due to side effects and is trying alternatives like vitamin D supplementation, scalp massages, cold showers, oil treatments, zinc shampoo, and dermarolling. They report improved scalp health and some new hair growth, despite skepticism from others about the effectiveness of these methods.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

N-Acetyl-Cysteine (NAC) was found to improve hair parameters in men with early-onset androgenetic alopecia, showing increased terminal hair count and decreased vellus hair count, with good tolerability. NAC, used alone or with minoxidil, may help due to its antioxidant properties, though its effectiveness can vary among individuals.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

N-Acetyl-Cysteine (NAC) is being explored for treating hair loss, but users report mixed results. Some also mention using Quercetin and Resveratrol without significant hair improvement.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.